Search PubMed⌕ Search

Biomedical subjects

M Wender

Publications and source records attributed to M Wender.

At least 217 records · Page 12Linked to original sources
PubMedDate not supplied

[Circulating immune complexes in multiple sclerosis].

Circulating immunocomplexes were detected in sera from MS patients using solid-phase ELISA anti-C3 method. Estimations have revealed positive results in 71% of 21 MS cases. They were positive in 73% of MS cases with relapse-remitting course and in 66% of MS cases with chronic-progressive course compared with 5% among controls. The concentration of immunocomplexes in serum was 62 +/- 4 micrograms/ml in patients with chronic-progressive course and was significantly higher than the concentration of immunocomplexes in patients with relapse-remitting course of the disease--40.1 +/- 5.1 micrograms/ml.

Antigen-Antibody Complex↗
PubMedDate not supplied

[Late results of alternate treatment of multiple sclerosis with encorton and decaris].

A group of 18 patients with clinically definite multiple sclerosis were subjected to alternate treatment with Prednisone (Polfa) and Decaris (Richter). The results were compared with those in a control group of 18 cases treated exclusively with Prednisone during exacerbations of the disease. The results indicate that the alternate treatment has not any significant effect on the course of multiple sclerosis, evaluated by the Kurtzke disability scale. The alternate treatment with a mild immunosuppression Encorton and immunomodulation-Decaris (Levamisole) leads to significant decrease of relapses in comparison with the period before the treatment, as well as in comparison with the control group treated exclusively with Encorton in case of exacerbations.

Adjuvants, Immunologic↗
PubMedDate not supplied

[Results of one-year treatment of multiple sclerosis with azathioprine compared with the therapy using small doses of Encorton].

A group of 21 patients with clinically confirmed multiple sclerosis were treated for one year with azathioprine, Germed, in daily doses of 50 or 75 mg depending on body weight. After two months the treatment was stopped for one month. The control group received prednisone (Encorton, Polfa) 5 or 10 mg daily. The drugs were given in wafers in powdered form. The double blind method was used. After one year the comparison of both groups failed to show any significant differences, and the reduction in the indices of exacerbations and stabilization of the process evaluated by Kurtzke's scale were nearly identical. However, this might have been due to the fact that nearly one-third of the patients dropped out from both groups. During the treatment with azathioprine no significant differences were noted in the surface phenotypes of peripheral blood mononuclear cells.

Adult↗
PubMedDate not supplied

[Erythrocyte complement receptor (C3b) expression in multiple sclerosis].

The study was carried out in 121 patients with multiple sclerosis and a control group of 519 healthy individuals. In 13 cases of multiple sclerosis and 12 controls family studies were carried out. Complement receptors (C3bR) on the erythrocytes were demonstrated by the haemagglutination test using human IgG heat-aggregated and guinea pig serum which served as a source of complement. On the basis of haemagglutination intensity and results of radioimmunoassay three phenotypes of complement receptor were isolated: high HH(C3bRh/C3bRh) producing strong agglutination, medium HL (C3bRh/Cbl) producing weak agglutination, and low phenotype LL (C3bR1/Cbl) in which no visible agglutination of erythrocytes was noted. Considerable differences were observed in the distribution of these phenotypes between controls and multiple sclerosis patients in whom the low phenotype (C3bR1/C3bR1) was more frequent. Family studies of controls suggested presence of two codominant alleles C3bRh and C3bR1 with Mendelian inheritance while similar studies of multiple sclerosis patients it was found that e.g. a child with multiple sclerosis whose parents had high C3bR phenotypes, that it were homozygotes for the C3bRh gene, had low phenotype. On the other hand, the high phenotype was found in a child of a female multiple sclerosis patient with the low phenotype (C3bR1/C3bR1). These observations suggest that reduced expression of the complement receptor on the erythrocytes depends in multiple sclerosis on the disease process in the first place, and not on genetic factors.

Adult↗
PubMedDate not supplied

[Anti-GFAP antibodies in the cerebrospinal fluid of patients with multiple sclerosis and other neurologic diseases].

The antibodies against glial fibrillary acidic protein (GFAP) in the CSF of patients with multiple sclerosis and other neurological diseases were determined. It was shown that the binding activity of CSF IgG with GFAP was higher in patients with MS and other organic neurological diseases as compared to control group (neurotics). The results support the idea, that in SM there is a general immune dysregulation, leading to production of a variety of autoantibodies against different antigens, including the presently shown GFAP.

Autoantibodies↗
PubMedDate not supplied

[Changes in stroke mortality rates during the years 1977 and 1985].

The mortality from stroke in the years 1977 and 1985 was compared in the Province of Poznań. The mortality from strokes decreased in that time period considerably in the population of males and females. The differences were significant from the age group 40-49 years. Reduced mortality from stroke in the Province of Poznań contrasted with a reverse trend in the mortality from ischaemic heart disease, which has been increasing continuously. It may be supposed that increasing effectiveness in the treatment of arterial hypertension may explain, in part at least, reduction of the mortality index from strokes. One cannot exclude, however, taht partial elimination of other risk factor due to changed way of life, changed dietary habits, may play also a considerable role in the positive trends in the epidemiology of strokes.

Adult↗
PubMedDate not supplied

[Late results of the treatment of the chronic progressive form of multiple sclerosis by intensive immunosuppression].

A group of 16 patients with secondary chronic progression of multiple sclerosis treated by short-lasting intensive immunosuppression (cyclophosphamide with ACTH) by the programme of Hausser et al (4) was compared with a clinically similar group of 16 patients treated exclusively with intramuscular ACTH. During 2 years of observation of the patients it was observed that short-lasting intensive immunosuppression induced with simultaneous administration of cyclophosphamide and ACTH had no beneficial effect on the slowly progressing form of multiple sclerosis. The observation leads to the conclusion that cyclophosphamide therapy should not be used in view of absence of favourable effect on the course of multiple sclerosis and the risk of increased frequency of malignant neoplasms which cannot be ruled out in this method.

Adrenocorticotropic Hormone↗
PubMedDate not supplied

[Early results of the treatment of chronic progressive forms of multiple sclerosis with cyclophosphamide and ACTH].

A group of 16 patients with chronic-progressing type of multiple sclerosis treated by intense immunosuppression (cyclophosphamide and ACTH) were followed-up for one year after completion of therapy. The results were compared with the observation of a control group of 16 patients with a similar type of multiple sclerosis. The choice of the type of therapy was done at random, and the results were assessed by a doctor who ignored the type of therapy used. In only a part of the observed cases stabilization of the disease process was observed, in a greater number in the cases treated with cyclophosphamide and ACTH than in the those treated with ACTH alone. However, the duration of follow-up is regarded as too short for reaching final conclusions regarding the effect of therapy on the course of this type of multiple sclerosis.

Adrenocorticotropic Hormone↗
PubMedDate not supplied

[Surface phenotypes of peripheral blood mononuclear cells in multiple sclerosis].

Using monoclonal antibodies the subpopulations of mononuclear cells were studied in peripheral blood in patients with multiple sclerosis in active phase of the disease. The results suggested the following conclusions: 1. In the active phase of multiple sclerosis (during exacerbations and slowly progressive course) a rise occurs in the proportions of Ia-positive and M1-positive cells without changes in the proportions of T4 and T8 lymphocytes and in their mutual ratio. 2. No differences were observed in the percent of peripheral blood mononuclear cells between all patients in the active phase of the disease and those with slowly progressing disease. 3. During immunomodulatory treatment (alternating administration of prednisone and levamisole) a rise was observed in the percent of suppressor cells T8/Ia-positive, and a fall in the T4/T8 suppressor cell ratio.

Adult↗
PubMedDate not supplied

[Effect of ACTH therapy on IgG synthesis in cerebrospinal fluid spaces in patients with disseminated sclerosis].

In 33 cases of multiple sclerosis treated with ACTH (2500 u during 40 days) IgG and albumins were determined in the serum and cerebrospinal fluid by Mancini's method. These determinations served for calculation of the IgG: albumin ration and IgG index. After the treatment a significant reduction was found of the serum level of IgG and IgG index, without significant changes in albumin concentration. The effect of ACTH therapy on IgG synthesis within the CSF spaces was not significant in the whole group. In the subgroup of patients with initially demonstrated IgG synthesis within the CSF spaces (before the treatment) a significant decrease was found of the IgG index and a non-significant decrease of the absolute IgG level in the CSF. A comparison of the results with our previous investigations shows that ACTH, despite its positive effect on multiple sclerosis exacerbations exerts a much weaker effect on the local IgG synthesis in the central nervous system than high doses of prednisone, despite an evident reduction of serum IgG level by ACTH.

Adrenocorticotropic Hormone↗
PubMedDate not supplied

[IgG synthesis in the cerebrospinal fluid in patients with the chronic progressive phase of multiple sclerosis treated with cyclophosphamide and ACTH].

In 30 cases of multiple sclerosis in the chronic-progressive phase treated with cyclophosphamide (total dose 4000 mg) and ACTH (total dose 1050 units) IgG and albumin were determined in the serum and cerebrospinal fluid by Mancini's method. From these determination the IgG, albumin ratio and the IgG index were calculated as markers of IgG synthesis in CSF spaces. As a result of these investigations it is suggested that the treatment of patients with multiple sclerosis in chronic-progressive phase with short-lasting intensive immunosuppression using cyclophosphamide and ACTH causes no significant changes in IgG synthesis in CSF spaces.

Adrenocorticotropic Hormone↗
PubMedDate not supplied

[Late results of the treatment of multiple sclerosis with large doses of Enkorton].

A group of MS patients treated with large doses of Prednisone (3960 mg over a period of 54 days with initial dose 200 mg per day) was observed during 4 years after the therapy and the results were compared with the control group treated with medium doses of Prednisone (initial dose 60 mg). The difference between two therapeutic groups estimated according to Kurtzke disability scale is statistically not significant. We cannot also conclude, that the large doses of Prednisone decrease the relapse rate. However it should be stressed that in patients treated with megadoses of Prednisone the secondary chronic progressive course of MS, more rarely developed than in cases treated with medium doses.

Clinical Trials as Topic↗